miR-339-5p inhibits cell migration and invasion in vitro and may be associated with the tumor-node-metastasis staging and lymph node metastasis of non-small cell lung cancer

Oncology Letters

Volumn 8, Issue 2, 2014, Pages 719-725

  Li, Yun ^a,b   Zhao, Weiguo ^b   Bao, Pengtao ^b   Li, Chunsun ^a   Ma, Xiu Qing ^a   Li, Yanqing ^a   Chen, Liang An ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b 309TH HOSPITAL OF PLA   (China)

Author keywords

Lung carcinoma; Lymph node metastasis; microRNAs; Tumor node metastasis staging

Indexed keywords

MICRORNA; MICRORNA 339 5P; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN;

ADULT; ARTICLE; BIOINFORMATICS; CANCER STAGING; CELL CULTURE; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTION; RNA ISOLATION;

EID: 84902345655     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2165     Document Type: Article

References (28)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Lee Y, Ahn C, Han J, et al: The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419, 2003.
3. Lund E, Güttinger S, Calado A, et al: Nuclear export of microRNA precursors. Science 303: 95-98, 2004.
4. Lee Y, Jeon K, Lee JT, et al: MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 21: 4663-4670, 2002.
5. Rana TM: Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 8: 23-36, 2007.
6. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
7. Gibbons DL, Lin W, Creighton CJ, et al: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 23: 2140-2151, 2009.
8. Ceppi P, Mudduluru G, Kumarswamy R, et al: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 8: 1207-1216, 2010.
9. Sobin LH, Gospodarowicz MK, and Wittekind CH (eds). International Union Against Cancer: TNM Classification of Malignant Tumours. 7th edition. WileyBlackwell, New York, NY, 2010.
10. Wu ZS, Wu Q, Wang CQ, et al: MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer 10: 542, 2010.
11. Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688, 2007.
12. Frankel LB, Christoffersen NR, Jacobsen A, et al: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283: 1026-1033, 2008.
13. Edmonds MD, Hurst DR, Vaidya KS, et al: Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer 125: 1778-1785, 2009.
14. Dews M, Homayouni A, Yu D, et al: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38: 1060-1065, 2006.
15. Foekens JA, Sieuwerts AM, Smid M, et al: Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 105: 13021-13026, 2008.
16. Song G, Zhang Y and Wang L: MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 284: 31921-31927, 2009.
17. Yu F, Yao H, Zhu P, et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123, 2007.
18. Xiao F, Zuo Z, Cai G, et al: miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37 (Database issue): D105-D110, 2009.
19. Krek A, Grün D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005.
20. John B, Enright AJ, Aravin A, et al: Human microRNA targets. PLoS Biol 2: e363, 2004.
21. Lewis BP, Shih IH, Jones-Rhoades MW, et al: Prediction of mammalian microRNA targets. Cell 115: 787-798, 2003.
22. Phan RT, Saito M, Basso K, et al: BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol 6: 1054-1060, 2005.
23. Polo JM, Dell'Oso T, Ranuncolo SM, et al: Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10: 1329-1335, 2004.
24. Pinto AE, André S, Silva G, et al: BCL-6 oncoprotein in breast cancer: loss of expression in disease progression. Pathobiology 76: 235-242, 2009.
25. Yamamoto S, Tomita Y, Hoshida Y, et al: Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma. Ann Surg Oncol 11: 697-704, 2004.
26. + ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol Cancer Ther 11: 2610-2620, 2012.
27. Yamamoto S, Tomita Y, Hoshida Y, et al: Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastriccarcinoma. J Clin Oncol 21: 2537-2544.
28. Yamamoto S, Tomita Y, Hoshida Y, et al: Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res 10: 651-657, 2004.